University College London and New York University will host the trials, which are being conducted by medical device manufacturer Trod Medical, a specialist in focal ablation therapy.
The clinical teams at NYU and UCL presented last month at the 111th American Urological Association’s Annual Meeting in San Diego, California on patients treated with the device, which is called Encage.
